Drugs for the treatment of Parkinson's Disease
- 1 Introduction
- 2 Epidemiology of Parkinson's Disease
- 3 Levodopa in the treatment of Parkinson's Disease
- 4 Anticholinergic Drugs in the treatment of Parkinson's Disease
- 5 MAO-B inhibitors in the treatment of Parkinson's Disease
- 6 Dopamine Agonist Drugs in the treatment of Parkinson's Disease
- 7 Physical Therapy Implications for Parkinson's Disease Drugs
- 8 Conclusion
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder that affects motor function. This disease has become an epidemic, affecting approximately 1 percent of individuals over the age of 65 years old . It is caused by decreased dopamine production in the basal ganglia due to degeneration of dopamine-secreting neurons ,. Initially, PD sufferers may be asymptomatic with the first clinical symptoms appearing after 60% of the dopaminergic neurons have degenerated in the substantia nigra . Cardinal symptoms of Parkinson disease include bradykinesia, akinesia, rigidity, and resting tremors ,. The exact cause of PD is unknown; however, contributing factors to may include trauma, infection, cortical degeneration, antipsychotic drugs and cerebrovascular disease . If PD goes untreated, total incapacitation will occur due to uncontrolled motor problems. This is why it is extremely important for PD patients to be prescribed the proper drug regimen.
- Harris PE ,C. K. Prevalence of complementary and alternative medicine (CAM) used by the general population: a systematic review and update. NCBI. https://www.ncbi.nlm.nih.gov/pubmed/22994327. October, 2012. Accessed November 5, 2018.
- Chen JJ, Nelson MV, Swope DM. Parkinson’s disease. DiPiro JT, Et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: Mcgraw-Hill. 2011.
- Parent M, Parent A. Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship. NCBI. https://www.ncbi.nlm.nih.gov/pubmed/20481265. May, 2010. Accessed November 5, 2018.
- Lecht, S., Haroutiunian, S., Hoffman, A., & Lazarovici, P. Rasagiline – A Novel MAO B Inhibitor in Parkinson’s Disease Therapy. NCBI. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386362/. June, 2007. Accessed November 5, 2018.
- Garcia Ruiz PJ, Catalan MJ, Fernandez Carril JM. Initial motor symptoms of Parkinson disease. NCBI. https://www.ncbi.nlm.nih.gov/pubmed/22045320. November 17, 2011. Accessed November 5, 2018.
- Gelabert-Gonzalez M, Serramito-Garcia R, Aran-Echabe E. Parkinsonism secondary to subdural haematoma. NCBI. https://www.ncbi.nlm.nih.gov/pubmed/22527627. July, 2012. Accessed November 5, 2018.
- Gupta D Kuruvilla. Vascular parkinsonism: what makes it different? NCBI. https://www.ncbi.nlm.nih.gov/pubmed/22121251. December, 2011. Accessed November 5, 2018.
- Lopez-Sedon JL, Mena MA, de Yebenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. NCBI. https://www.ncbi.nlm.nih.gov/pubmed/22250585. February, 2012. Accessed November 5, 2018.
- Mazokopakis EE, Koutras A, Starakis I, Panos G. Pathogens and chronic or long-term neurologic disorders. NCBI. https://www.ncbi.nlm.nih.gov/pubmed/21446901. March, 2011. Accessed November 5, 2018.